Literature DB >> 11855877

Survival among U.S. women with invasive epithelial ovarian cancer.

Valerie McGuire1, Christine A Jesser, Alice S Whittemore.   

Abstract

OBJECTIVE: Invasive epithelial ovarian cancer is a highly fatal disease, diagnosed at advanced stages when survival is poor. Relatively little is known about the variation in survival across U.S. women of different race/ethnicities. To investigate this issue, we evaluated pathological characteristics and death rates due to invasive epithelial ovarian cancer in a population-based sample of patients from six racial/ethnic groups.
METHODS: The analysis included 38,012 women diagnosed with primary invasive epithelial ovarian cancer between 1973 and 1997 in the Surveillance, Epidemiology and End Results Program of the National Cancer Institute.
RESULTS: Filipina patients were younger at diagnosis, more likely to have localized disease, and had more mucinous cancers than whites. African-Americans were more likely than whites to be diagnosed at older ages, with distant disease and with undifferentiated/unclassified cancers. After adjusting for age at diagnosis, stage of disease at diagnosis, and cancer histology, we found that, compared to whites, death rates were significantly elevated among African-Americans and significantly reduced among Hispanics and Filipina. We also found that death rates declined significantly with time since diagnosis among women with advanced disease.
CONCLUSION: The declining death rates in women with advanced disease suggest the presence of considerable prognostic heterogeneity among these women, which could reflect differences in quality of care. This issue, as well as the survival disadvantage for African-American women and survival advantages for Hispanic and Filipina women, needs investigation.

Entities:  

Mesh:

Year:  2002        PMID: 11855877     DOI: 10.1006/gyno.2001.6536

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  48 in total

1.  MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Authors:  Chandra Bartholomeusz; Tetsuro Oishi; Hitomi Saso; Ugur Akar; Ping Liu; Kimie Kondo; Anna Kazansky; Savitri Krishnamurthy; Jangsoon Lee; Francisco J Esteva; Junzo Kigawa; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2011-12-05       Impact factor: 6.261

2.  Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Authors:  Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

3.  The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.

Authors:  Carmel Pezaro; Paul James; Joanne McKinley; Mary Shanahan; Mary-Anne Young; Gillian Mitchell
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

4.  Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Chunqiao Tian; Franco Muggia; Rajiv Dhir; Deborah K Armstrong; Michael A Bookman; Laura J Niedernhofer; Julie Deloia; Michael Birrer; Thomas Carl Krivak
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

5.  Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

Authors:  Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby
Journal:  J Natl Cancer Inst       Date:  2013-03-28       Impact factor: 13.506

6.  Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.

Authors:  Kosuke Yoshihara; Atsushi Tajima; Tetsuro Yahata; Shoji Kodama; Hiroyuki Fujiwara; Mitsuaki Suzuki; Yoshitaka Onishi; Masayuki Hatae; Kazunobu Sueyoshi; Hisaya Fujiwara; Yoshiki Kudo; Kohei Kotera; Hideaki Masuzaki; Hironori Tashiro; Hidetaka Katabuchi; Ituro Inoue; Kenichi Tanaka
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

7.  Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.

Authors:  Stacey J Winham; Ailith Pirie; Yian Ann Chen; Melissa C Larson; Zachary C Fogarty; Madalene A Earp; Hoda Anton-Culver; Elisa V Bandera; Daniel Cramer; Jennifer A Doherty; Marc T Goodman; Jacek Gronwald; Beth Y Karlan; Susanne K Kjaer; Douglas A Levine; Usha Menon; Roberta B Ness; Celeste L Pearce; Tanja Pejovic; Mary Anne Rossing; Nicolas Wentzensen; Yukie T Bean; Maria Bisogna; Louise A Brinton; Michael E Carney; Julie M Cunningham; Cezary Cybulski; Anna deFazio; Ed M Dicks; Robert P Edwards; Simon A Gayther; Aleksandra Gentry-Maharaj; Martin Gore; Edwin S Iversen; Allan Jensen; Sharon E Johnatty; Jenny Lester; Hui-Yi Lin; Jolanta Lissowska; Jan Lubinski; Janusz Menkiszak; Francesmary Modugno; Kirsten B Moysich; Irene Orlow; Malcolm C Pike; Susan J Ramus; Honglin Song; Kathryn L Terry; Pamela J Thompson; Jonathan P Tyrer; David J van den Berg; Robert A Vierkant; Allison F Vitonis; Christine Walsh; Lynne R Wilkens; Anna H Wu; Hannah Yang; Argyrios Ziogas; Andrew Berchuck; Georgia Chenevix-Trench; Joellen M Schildkraut; Jennifer Permuth-Wey; Catherine M Phelan; Paul D P Pharoah; Brooke L Fridley; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-01-08       Impact factor: 4.254

8.  Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.

Authors:  John H Farley; Chunqiao Tian; G Scott Rose; Carol L Brown; Michael Birrer; G Larry Maxwell
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

9.  The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago.

Authors:  Charlotte E Joslin; Katherine C Brewer; Faith G Davis; Kent Hoskins; Caryn E Peterson; Heather A Pauls
Journal:  Gynecol Oncol       Date:  2014-08-28       Impact factor: 5.482

10.  Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US.

Authors:  Maria Theresa M Redaniel; Adriano Laudico; Maria Rica Mirasol-Lumague; Adam Gondos; Gemma Leonora Uy; Jean Ann Toral; Doris Benavides; Hermann Brenner
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.